Birkenhauer Peter, Yang Zhihong, Gander Bruno
Institute of Pharmaceutical Sciences, ETH Hönggerberg HCI, 8093 Zürich, Switzerland.
J Pharm Pharmacol. 2004 Nov;56(11):1339-56. doi: 10.1211/0022357044797.
Restenosis is the major limitation of the successful therapy of percutaneous coronary intervention (PCI) for patients with coronary artery disease. The problem was appreciated in the late 1970s to early 1980s. Only in recent years, anti-restenotic therapy has achieved a breakthrough with the development of drug-eluting stents. Here, we provide an overview about pathological mechanisms of restenosis after PCI. Present therapeutic approaches to overcome restenosis and recent clinical results are revisited, and some major concerns in the post-drug-eluting stent era are discussed.
再狭窄是冠状动脉疾病患者经皮冠状动脉介入治疗（PCI）成功后的主要限制因素。这个问题在20世纪70年代末到80年代初就已被认识到。直到近年来，随着药物洗脱支架的发展，抗再狭窄治疗才取得突破。在此，我们概述了PCI术后再狭窄的病理机制。回顾了目前克服再狭窄的治疗方法和近期临床结果，并讨论了药物洗脱支架时代后的一些主要问题。
